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Despite the large number of drugs available for the treatment of asthma, in
5–10% of the patients this disease is not well controlled. While most treatments
palliate symptoms, those suffering from severe and uncontrolled asthma could
benefit more from a therapeutic approach addressing the root problem. An
siRNA-based therapy targeting the transcription factor GATA3 in activated T
helper cells subtype 2 (TH2 cells), one of the key upstream factors involved in
asthma, could therefore represent a promising strategy. However, the difficult-
to-transfect cell type has not extensively been explored for nucleic acid thera-
peutics. In this regard, our group first identified a suitable pathway, that is,
transferrin receptor mediated uptake, to target efficiently and specifically acti-
vated TH2 cells with a transferrin-polyethyleneimine (PEI) conjugate which
forms polyplexes with siRNA. This system, despite efficient uptake in activated
T cells (ATCs) in vivo, suffered from poor endosomal release and was later
improved by a combination with a melittin-PEI conjugate. The new formula-
tion showed improved endosomal escape and gene silencing efficacy. Addition-
ally, in order to develop a clinically relevant dosage form for pulmonary
delivery of siRNA we have lately focused on a dry powder formulation by spray
drying (SD) for the production of inhalable nano-in-microparticles. In proof-of-
concept experiments, DNA/PEI polyplexes were used in order to implement
analytics and engineer process parameters to pave the way for SD also siRNA
containing polyplexes and more sophisticated systems in general. Ultimately,
our efforts are devoted to the development of a novel treatment of asthma that
can be translated from bench to bedside and are reviewed and discussed here
in the context of the current literature.
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1 | INTRODUCTION
Amongst chronic inflammatory diseases of the airway, asthma is still considered a great medical and socioeconomic
burden under which nearly 340 million people suffer worldwide (The Global Asthma Report 2018, 2018). The disease
hallmarks, besides persistent lung inflammation, are shortness of breath, mucus hypersecretion, broncho obstruction
with enhanced reactivity to spasmogens (airway hyperactivity), and airway remodeling (Sel et al., 2008; The Global
Asthma Report 2018, 2018; Weckmann et al., 2007; Wegmann et al., 2005). The current asthma treatment algorithm is
based on bronchodilating and anti-inflammatory agents (inhaled and/or systemic glucocorticoids) targeting symptoms
only. However, in a small subset of patients these symptoms cannot be controlled even with high doses of the rec-
ommended drugs (de Groot, Ten Brinke, & Bel, 2015).
The origin of these symptoms, amongst others is the activation, infiltration and accumulation of T cells positive for
the cluster of differentiation 4, also known as T helper cells (TH2 cells), of subtype 2 (CD4
+TH2 cells) into major airways
and mucosa of small airways, and the subsequent release of proinflammatory cytokines (IL-4, IL-5, IL-9, and IL-13) (Sel
et al., 2008; Walker, Barlow, & McKenzie, 2013; Weckmann et al., 2007; Wegmann et al., 2005). After it was found that
the release of these interleukins is triggered by an upregulation of the GATA-binding protein 3 (GATA3) in TH2 cells
upon activation (Ray & Cohn, 1999), GATA3, a transcription factor regulating T cell differentiation into TH2 cells,
emerged as a powerful therapeutic target (Krug et al., 2017). Considering that the effect of silencing only single cyto-
kines can be overcompensated by others (Lively et al., 2008), therapeutic downregulation of GATA3, preventing down-
stream release of all TH2 cytokines and concomitant symptoms in parallel holds great promise.
A powerful tool for post-transcriptional gene silencing is RNA interference (RNAi): Fire and Mello who earned the
Nobel Prize, discovered a nuclease complex known as RNA induced silencing complex (RISC) which recognizes and
destroys target mRNAs. The target is specifically identified by small interfering RNAs (siRNA) which are RNA strands
of 21–25 base pairs with base-complementarity to the target mRNA. Upon pairing of the activated RISC with single-
stranded siRNA and the complementary mRNA site, cleavage of mRNA is initiated and the translation of the protein
alongside the degraded mRNA is prevented (Hannon, 2002). Accordingly, targeting mRNA coding for GATA3 with
siRNA could enable post-transcriptional gene silencing of the transcription factor which is overexpressed in activated
TH2 cells. Subsequently, downregulating the overexpressed level towards a more physiologic one could therapeutically
be exploited towards a new asthma treatment without general immunosuppressive side effects. Delivering siRNA exoge-
nously into activated TH2 cells, however, is not a simple task.
Considering the macromolecular nature of siRNAs which are highly negatively charged and the lack of nucleic acid
specific active transporters on cell membranes in combination with ubiquitously present nucleases which quickly
degrade siRNA in the body, intracellular siRNA delivery requires formulation of the latter. Compared to viral vectors,
nonviral vectors are more advantageous regarding safety, manufacturability and immunogenicity (Ruigrok, Frijlink, &
Hinrichs, 2016). Positively charged polymers are one class of nonviral vectors where polyethyleneimine (PEI) and its
derivatives are the most studied representatives. These polymers form so called polyplexes on the nano-scale by electro-
static interaction with siRNA protecting it on the one hand from nucleases and enabling internalization and release
into cells on the other (Liu, Nguyen, Steele, Merkel, & Kissel, 2009). However, in case of intracellular delivery into T
cells, additional barriers, such as endosomal release, need to be considered (Olden, Cheng, Yu, & Pun, 2018).
In addition to avoiding nucleases which are present in high concentrations in blood but in very low concentrations
in lung lining fluids, pulmonary administration of nucleic acids also avoids the rapid distribution within the body upon
systemic delivery which comes with possible side effects (Weber, Zimmer, & Pardeike, 2014). Local pulmonary delivery
can be achieved by inhaling particles (liquid or solid) of an aerodynamic size between 1 and 5 μm. Greater particles are
deposited in the throat and upper airways unable to reach the area of interest. Smaller particles can undergo insuffi-
cient sedimentation and are exhaled. For optimal lung deposition, dry powder formulations are favored for siRNA
delivery despite more complex formulation and preparation as compared with aerosolization (Chow & Lam, 2015). The
advantages can be easily explained by increased physical and chemical stability and the resulting prolonged shelf life
due to the absence of water and nucleases (Keil & Merkel, 2019). Typical procedures to produce inhalable powders are
spray drying (SD) or a combination of SD and lyophilization—spray–freeze drying—of drug only or drug-excipient
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combinations (Okuda et al., 2018). For the latter, solutions or suspensions are sprayed into liquid nitrogen resulting in
frozen particles which are lyophilized afterwards to remove residual water. However, this process requires high energy
and time consumption due to long lyophilization cycles. A more straight forward process is SD where droplets are gen-
erated and dried by hot air (Schulze et al., 2018). This technique leads to microparticles where polyplexes or other
nanoparticles are embedded in an excipient matrix resulting in nano-in-microparticles which ideally resuspend into
nanoparticles upon impaction on lung fluid.
This article highlights our previous and ongoing research regarding polyplexes designed for pulmonary delivery for
the treatment of lung diseases in general, and of asthma specifically in the context of the current literature.
2 | TH2-CELL TARGETING
In the pathogenesis of asthma, TH2 cells play a central role in orchestrating the allergic reaction. Upon activation and
concomitant upregulation of GATA3, TH2 cells secrete IL-4, IL-5, IL-9, IL-13, and tumor necrosis factor-alpha (TNF-α)
(Barnes, 2002; Ishmael, 2011). As shown in Figure 1, these cytokines stimulate different cell types resulting in further
downstream effects and symptoms known for asthma. Although symptoms were shown to be reduced by
i.v. application of antibodies against single interleukins in mice, their use is limited due to whole body distribution after
systemic administration resulting in various side effects (Wegmann, 2009) and due to lack of compliance if adminis-
tered clinically.
Rather than blocking or downregulating single cytokines, post-transcriptional interference with GATA3 expression
has been reported to be a promising approach using intratracheal instillation with a bolus of GATA3 shRNA lentiviral
vector (Lee, Huang, & Chiang, 2007) or intranasal treatment with GATA3 DNAzyme (Dicke, Wegmann, Sel, Renz, &
FIGURE 1 T helper-2 (TH2) cells in asthma pathogenesis. Inhaled allergens are thought to be processed by two mechanisms in
asthmatic airways. Allergens either: (1) activate mast cells through cross-linking with IgE on their cell surfaces through the high-affinity
type 1 IgE receptor (FcɛR1) to release mediators that induce bronchoconstriction, such as histamine, cysteinyl leukotrienes, and
prostaglandin D2 (PGD2) or (2) are processed by dendritic cells, which are induced to secrete the CC chemokine ligand (CCL) 17 and CCL22
by thymic stromal lymphopoietin (TSLP). Dendritic cells then attract and activate TH2 cells by the binding of CCL17 and CCL22 with CC
chemokine receptor 4 (CCR4) on the TH2 cell surface. IL-33 is produced by airway epithelial cells and activates dendritic cells and TH2 by
inducing the release of TNF-α from mast cells. TH2 secretes cytokines, including IL-4 and IL-13, which switch B cells to produce IgE, IL-5,
which promotes the development and survival of eosinophils, and IL-9, which activates mast cells. Once IL-13 is produced, it can increase
the survival and migration of eosinophils, and it promotes activation of macrophages to create an M2, or an allergic cell phenotype. Airway
epithelial cells are stimulated, and through mediators such as periostin and transforming growth factor β1 (TGF-β1), they can increase
airway inflammation and lead to the increased permeability of airway epithelial cells and mucous hypersecretion. IL-13 also has direct
effects on airway smooth muscle, leading to increased contraction to agonists such as acetylcholine and decreased relaxation with beta-
agonists. (Reproduced with permission from Thomson, Patel, and Smith (2012). Copyright 2012 Dove Medical Press Ltd.)
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Garn, 2007). In those experiments, however, the therapeutic nucleic acids were administered as unstable, free DNA and
were not specifically targeted towards TH2 cells.
The downregulation of GATA3 in activated TH2 cells via pulmonary administration is therefore preferred as the
secretion of TH2 cytokines is ideally only downregulated in the activated T cells (ATCs) in the lung, preventing side
effects of general immune suppression. It is furthermore expected that gene silencing via siRNA will not mediate a full
knock out of GATA3 but rather downregulation of a pathologically upregulated gene to a physiologic level. However,
the transfection of T cells is challenging since they do not express caveolin and are devoid of caveolae, preventing them
from active endocytosis of nanoparticles. Primary T cells are thus known to be resistant to common nonviral delivery
vectors (Montixi et al., 1998).
Since viruses efficiently transduce T cells, we sought to find a virus-like tool to target activated TH2 cells specifically
and efficiently in a receptor-mediated manner. While in the 1980s, an overexpression of transferrin receptor (CD71) in
ATCs was found whereas naïve T cells lacked the expression of CD71 (Galbraith, Werner, Arnaud, & Galbraith, 1980;
Neckers & Cossman, 1984), this finding had so far not been exploited for nucleic acid delivery to T cells. This idea was
picked up by our group in the early 2010s. First experiments were conducted to confirm differential receptor expression
in naïve versus ATCs and to test whether receptor mediated uptake was possible ex vivo in primary T cells exploiting
transferrin (Tf) as a targeting ligand (Kim, Nadithe, Elsayed, & Merkel, 2013). Therefore, in proof-of-concept experi-
ments, low molecular weight PEI was conjugated to Tf (Tf-PEI) and complexed with fluorescently labeled siRNA into
polyplexes at different ratios. These formulations were initially only tested regarding intracellular delivery in primary T
cells ex vivo. As seen in Figure 2a, Tf-PEI polyplexes were significantly more efficiently taken up by ATCs compared to
blank, compared to unmodified PEI and even compared to the positive lipofectamine control. Also, no efficient uptake
was observed in naïve T cells for either formulation (Figure 2b), which was expected based on the lack of caveolae in T
FIGURE 2 Specific Uptake of siRNA in activated T cells with a Tf-PEI
conjugate. Uptake of Alexa488-labaled siRNA (a) at different N/P ratios into
fully activated T cells with high TfR expression (inset 2a), and (b) lack of
uptake into T cells with low TfR expression (inset 2b). The expression of
TfR in the T cells was confirmed by anti-CD71 antibody binding assay. The
siRNA taken up into T cells was analyzed by flow cytometry. Lipofectamine
was used as a positive control. (Reproduced with permission from Kim
et al. (2013). Copyright 2013 Elsevier B.V.)
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cells (Montixi et al., 1998). The activation dependent expression of CD71 in both activated and naïve primary T cells
was confirmed by anti-CD71 antibody binding assays (see Figure 2 insets). These results confirmed our hypothesis that
specific targeting of ATCs via transferrin is possible and further research was conducted.
While successful targeting of T cells was also shown by Ramishetti et al. (2015) after systemic administration of lipid
nanoparticles which were surface functionalized with an CD4+ antibody, no differentiation between resting and ATCs
was made as the intention was to target and downregulate T cell specific genes systemically. In contrast, CD71 targeting
results in the benefit of addressing only ATCs which are strongly involved in asthma.
To test specificity of Tf-PEI polyplexes towards ATCs in the complex environment of the lung, an in vivo bio-
distribution study was performed in a murine asthma model in comparison to healthy control groups: Mice were intra-
tracheally administrated on four consecutive days with Tf-PEI or PEI polyplexes. After euthanizing animals,
bronchoalveolar lavage cells were collected to investigate the distribution of siRNA in different cells types (macro-
phages, eosinophils, type II pneumocytes, B, and T cells). We observed a specific uptake in T cells in comparison to the
other investigated cell types. In line with the previous ex vivo study, the uptake in TH2 cells was also significantly
higher in asthmatic than in healthy mice (Xie et al., 2016). In healthy animals, only macrophages took up siRNA inde-
pendent of the formulation, and nontargeted PEI mediated uptake in type II epithelial cells and macrophages in both
inflamed and healthy animals. However it has been described that macrophages do not express GATA3 (Saraiva &
O'Garra, 2010), which leads us to hypothesize a lack of severe side effects due to nanoparticle delivery to macrophages.
Type II pneumocytes, however, do express GATA3 and are involved in TH2 cytokine production. Therefore, nonspecific
delivery to lung epithelial cells is expected to have a positive, anti-inflammatory effect. Since GATA3 does however
have a protective effect, for example in mammary luminal cells (Chu et al., 2012), we will investigate biodistribution of
siRNA after pulmonary delivery to assess potential risks and side effects of the treatment.
2.1 | Optimization of endosomal release: Tf-Mel-PEI
After confirming effective targeting and uptake of Tf-PEI polyplexes in TH2 cells in the lung, their therapeutic efficacy
was tested in vivo by evaluating the knockdown of GATA3 and subsequent downstream effects. Despite significantly
higher gene silencing rates of Tf-PEI compared to PEI ex vivo in primary TH2 cells (Xie et al., 2016), a single treatment
with Tf-PEI polyplexes did not result in significant gene silencing of GATA3 in lung tissue or of IL13 in pulmonary T
cells, as determined by quantitative real-time PCR (qRT-PCR) and intracellular cytokine staining, respectively (Kandil,
Feldmann, Xie, & Merkel, 2019). The reason for the lack of significant gene silencing was hypothesized to depend on
the single administration and/or on insufficient endosomal escape of the nanocarrier after endocytosis.
Endosomal escape represents a crucial factor and is considered the rate-limiting step in cytoplasmatic delivery of
nanoparticle-based therapies. In fact, a failure of escape would result in a probable degradation of the cargo in the
lysosome which merges with the late endosome, leading to a loss of therapeutic activity (Smith, Selby, Johnston, &
Such, 2019). Several strategies have been proposed to overcome this problem, such as including positively charged or
pH-sensitive moieties able to disrupt the endosomal membrane (Selby, Cortez-Jugo, Such, & Johnston, 2017). In this
respect, it is to be noted that endosomal acidification, leading to the so-called proton sponge effect and osmotic rup-
ture of polyamine-loaded endosomes, is slower and less robust in T cells as compared to epithelial cell lines (Olden,
Cheng, Cheng, & Pun, 2019). In this view, the use of melittin, a pore-forming peptide, was hypothesized to yield more
efficient endosomal escape. Melittin is a peptide derived from bee venom and consisting of 26 amino acids that has
an inherent capacity to disrupt cell membranes also at acidic pH. Moreover, this peptide was shown to be effective as
a delivery system for siRNA itself, being able to reach significant transfection efficiencies (Hou, Pan, Lanza, &
Wickline, 2013). Additionally, a virus-inspired polymer for efficient in vitro and in vivo gene delivery, called VIPER
(Cheng, Yumul, & Pun, 2016), containing melittin, had been shown to efficiently mediate gene silencing in the lung
of healthy mice and had been tolerated very well after pulmonary delivery (Feldmann et al., 2018). Based on these
observations, we decided to include melittin in our Tf-PEI conjugate to improve the endosomal escape. However,
melittin was modified by 2,3-dimethyl-maleic anhydride (DMMAn) to reduce side effects by directing its activity to
acidic pH and hence to the endosomal membrane only. Thus, general membrane activity was reduced, and this
melittin derivative was conjugated to PEI and blended with different ratios of Tf-PEI. As a result, we obtained a deliv-
ery system which retained its selectivity towards ATCs due to the presence of transferrin at improved endosomolytic
activity (Kandil et al., 2019). The new blend composed of Tf-PEI and Mel-PEI (Tf-Mel-PEI, 50:50) displayed optimal
characterization parameters, showing particle sizes below 200 nm, low polydispersity indices and stability in lung
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lining fluids. In line with the results obtained with the Tf-PEI conjugate, we achieved significant cellular uptake
results in both Jurkat and human primary ATCs in comparison to both free siRNA and siRNA/lipofectamine. More-
over, after determining binding kinetics of the different formulations with CD71 using Surface Plasmon Resonance
technique, we observed that Tf-Mel-PEI stably bound the transferrin receptor and also showed superior affinity over
Tf-PEI (Kandil, Xie, et al., 2019).
In the next step, the effect of melittin on the endosomal membrane was investigated via acridine orange staining of
living cells. This technique is based on a differential fluorescence emission of the cell-permeable nucleic acid binding
dye which emits red light if trapped in the endosome and green light if located within cytoplasmic pH. As shown in
Figure 3a, chloroquine, as positive control for successful endosomal release, as well as transfection with melittin-
containing conjugates resulted in efficient endosomal escape, reflected in a color change of the dye from red to green.
Positive and negative controls in fluorescence based assays with chloroquine treatment are especially important as chlo-
roquine is a mild base used to neutralize endosomal and lysosomal pH, and pH dependent dyes used to visualize these
compartments can potentially render a negative result in the presence of this drug. After transfection with the Tf-PEI
conjugate, only few green dots were detected while in PEI transfected cells, only red dye was found, supporting the
findings by Olden et al. describing a lack of endosomal acidification in T cells (Olden et al., 2018) resulting in
endosomal entrapment of PEI. Regarding endosomal escape, Tf-Mel-PEI clearly showed superior characteristics over
the previously used Tf-PEI formulations (Kandil, Xie, et al., 2019).
To determine whether the effect of improved endosomal escape was also reflected on higher mRNA down-
regulation, the knockdown of GAPDH was evaluated via qRT-PCR (Figure 3b). Indeed, in human primary ATCs the
Tf-Mel-PEI blend achieved higher gene silencing levels than Tf-PEI with 76% gene knockdown compared to 43%,
respectively (Kandil, Xie, et al., 2019). Most importantly, however, the increased endosomal escape was not paralleled




















































































FIGURE 3 (a) Acridine
orange staining of untreated
A549 cells (A1) and of A549 cells
after incubation of polyplexes
with Chloroquine (A2), PEI (A3),
Tf-PEI (A4), Mel-PEI (A5) and
Tf-Mel-PEI (A6). (b) GAPDH
knockdown in Jurkat cells
(B1) and human primary
activated T cells (B2) after
treatment with GAPDH-siRNA
or scrambled siRNA as negative
control. Data points indicate
mean ± SD, n = 3; One-way
analysis of variance, *p < .05,
**p < .01, *** p < .001.
(Reproduced with permission
from Kandil, Feldmann,
et al. (2019). Copyright 2019
Wiley)
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Our published efforts so far describe a formulation of Tf-Mel-PEI polyplexes with optimal particle characteristics
able to selectively target ATCs and improved endosomal escape and gene silencing efficacy. Tf-Mel-PEI was therefore
considered a suitable tool for follow up in vivo studies concerning in vivo specificity for ATCs, biodistribution and ther-
apeutic gene silencing efficiencies in a murine asthma model. Despite the fact that LMW-PEI and its Tf-PEI conjugate
have been tolerated well in healthy and asthmatic mice (Xie et al., 2016), we are currently developing oligospermine
derivatives to replace the PEI block in our approach (Elsayed et al., 2014). It is expected that in the inflamed lung, even
Tf-shielded LMW-PEI is not well tolerated, especially intracellulary where the disulfide bond between Tf and PEI will
be reduced. Therefore, nonbiodegradable PEI is not a promising approach for the treatment of a chronic disease, and
biodegradable alternatives are currently developed by us and others. By mimicking PEI with a polyamine that endoge-
nously acts as nucleic acid condenser, we believe that similar condensation efficacy of siRNA will be obtained at
reduced toxicity and immunogenicity but at increased biodegradability (Elsayed et al., 2014). In parallel, inhalable dry
powder formulations are being developed to pave the way for translation from bench to bed side.
2.2 | Pulmonary delivery of nucleic acids
Therapeutic approaches of delivering nucleic acids to the lung via inhalation benefit from direct accessibility and the
ease of its administration route. However, several barriers, such as the architecture of the lung, the presence of mucus
and surfactant, mucociliary clearance and phagocytosis by cells of the immune system, need to be overcome in the lung
for successful delivery of nucleic acids to their target cells and sites of action (Merkel & Kissel, 2012; Merkel, Zheng,
Debus, & Kissel, 2012). After carefully optimizing our formulations for gene silencing in T cells over the past years, we
are currently assessing their efficacy in 3D cell culture models (Zscheppang et al., 2018) and in mucus mobility assays
based on fluorescence correlation spectroscopy (Merkel et al., 2009). Current clinical trials for inhalable gene-based
therapies have been focused mainly on the use of viral and liposome-based vectors, such as in the case of cystic fibrosis,
to deliver cDNA for replacing the defective CFTR gene (Caplen et al., 1995; Griesenbach, Geddes, & Alton, 2004). How-
ever, transfection efficiency in the lung in these clinical trials was disappointing. The study and development of new
formulation strategies for inhalable gene therapies is therefore of paramount importance.
2.3 | Dry powder formulation
SD is the most straight forward technique to produce inhalable particles. Although several groups have applied SD to
obtain dry powder formulations of their nucleic acid formulations, analytics for characterizing nanoparticles before and
after SD have been very scarce. However, an understanding of changes between freshly prepared and redispersed
nanoparticles is needed to fully understand effects of tubing material, pump stress, shear forces and heat stress which
are applied to the particles during production (Jensen et al., 2010; Schulze et al., 2018). Loss of nucleic acid and or poly-
mer could ultimately lead to decreased in vitro and in vivo performance. Hence, we successfully developed and set up
protocols for nucleic acid as well as amine based polymer quantification to easily quantify the components of dried for-
mulations and redispersed suspensions (Keil et al., 2019). Additionally, the effect of mannitol and trehalose on the
redispersability of polyplexes consisting of 25k PEI and bulk DNA (bDNA) after SD was investigated. Both excipients
were chosen as they are generally recognized as safe substances, known for their lyo-and desicco-protection and com-
monly applied in SD (Vehring, 2008). We found that a distinct concentration of excipient was needed to preserve PEI-
bDNA polyplex size and particle distribution, independent of the excipient's nature. Initial changes in zeta potentials of
the formulations after SD and redispersion could also be eliminated. Furthermore, it was confirmed by cascade impac-
tion analysis that particles were prepared with an aerodynamic diameter between 1 and 5 μm, which is a conducive size
range for pulmonary administration. Scanning electron microscopy revealed round smooth microparticles for mannitol
based formulations and also round but partly fused trehalose based microparticles. These findings were explained by
the state of mannitol and trehalose via X-ray powder diffraction and differential scanning calorimetry revealing that
mannitol crystallized upon SD while trehalose formulations dried without forming a crystalline but an amorphous
state. This most probably led to the high residual moisture content of 3.2% of trehalose formulations compared to 0.4%
of mannitol formulations and hence the fusion of trehalose microparticles. However, crystallinity and water content
did not affect aerodynamic properties on short term. After establishing and ultimately applying the new set of analytical
methods to SD powders, important changes to the initial formulations were detected: trehalose formulations showed
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~32% nucleic acid loss at low N/P ratios reaching a plateau of ~20% at higher N/P ratios of the polymer/nucleic acid
polyplexes, suggesting a stabilizing effect of excess polymer (Figure 4a). Considering the measured polymer loss of the
different formulations after SD (Figure 4b), N/P ratios of the redispersed formulations overall increased (Figure 4c). It
was therefore hypothesized that the N/P increase at least partially explained the improved uptake and transfection effi-
ciency of redispersed formulations in vitro compared to their freshly prepared counterparts with and without excipient
as control (Figure 4d, e; Keil et al., 2019).
Even if both DNA and RNA are nucleic acids, we have more than once shown that circular plasmid DNA, for exam-
ple, behaves very differently from rigid, short double-stranded siRNA when condensed with cationic polymers (Zheng
et al., 2012). Therefore, our current research on dry powder formulations focuses on the preparation of polyplexes con-
sisting of siRNA and different PEI based delivery vectors with the goal of developing a platform technology for
inhalable nucleic acid formulations.
3 | CONCLUSION
siRNA-based therapies offer the chance to potentially target any single mRNA specifically and efficiently and mediate
its downregulation. In the treatment of asthma, this technique could be exploited to target GATA3 in activated TH2
cells, one of the main factors involved in the pathogenesis of asthma. Almost 10 years ago, our group started a journey
aimed to find a suitable delivery system able to downregulate GATA3 and to produce a final spray dried powder formu-
lation to be administered to patients via inhalation. After identifying transferrin as a targeting ligand for ATCs, we
developed the Tf-PEI conjugate, a delivery system that displayed high cellular selectivity and intracellular uptake with
high transfection efficiencies ex vivo. Due to insufficient in vivo gene silencing, however, this formulation was then
improved in terms of endosomal escape by blending it with the Mel-PEI conjugate. The new formulation showed opti-
mal particle characteristics and ex vivo parameters. In parallel, we have also focused on the development of a dry pow-
der formulation, an essential step to produce a final formulation that could be transferred from bench to bedside. We
FIGURE 4 Polymer and nucleic acid quantification. Quantification of (a) bulk DNA and (b) PEI in the 10% trehalose nano-in-
microparticle (NIM) formulations following spray drying; (c) comparing the redispersed N/P ratio with the initial N/P ratio of the PEI
polyplexes loaded with bulk DNA; (d) uptake and (e) transfection efficiency of redispersed NIM formulations in A549 cells. Median
fluorescence intensity (MFI) was determined by flow cytometry to evaluate efficiency of (d) fluorescently labeled bDNA or E) pEGFP in a
human nonsmall cell lung carcinoma cell line (A549) of fresh or redispersed polyplexes from 10% trehalose NIM formulations at N/P ratios
of 6, 8 and 10 with (d) 0.5 μg of bDNA or E) 0.75 μg of GFP plasmid in comparison to freshly prepared formulations in presence of trehalose.
Blank samples consisted of A549 cells treated with 5% glucose only. Data points indicate mean ± SD (n = 3). Two-way analysis of variance,
Bonferroni post-test, *p < .05, **p < .01, *** p < .001, ns, nonsignificant. (Reproduced with permission from Keil et al. (2019). Copyright
2019 Elsevier B.V.)
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successfully produced nano-in-microparticles with ideal characteristics while retaining high transfection efficacies after
redispersion.
Current research is therefore focusing on the in vivo testing of Tf-Mel-PEI in a murine asthma model and the dry
powder formulation of siRNA based polyplexes. Ultimately, both research fields will be combined and hopefully result
in a new therapy for the treatment of severe, uncontrolled asthma.
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